CASP9 and Miyoshi myopathy: This inhibitor did not only inhibit the growth in MM cells, the combination of MPT0G413 and bortezomib enhanced also polyubiquitinated protein accumulation and synergistically reduced MM viability, showing increased caspase-3, caspase-8, and caspase-9 levels (Huang et al., 2019).